Newcastle upon Tyne, United Kingdom

Duncan Charles Miller

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 18.3

ph-index = 3

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Duncan Charles Miller: Innovator in Anticancer Research

Introduction

Duncan Charles Miller is a notable inventor based in Newcastle upon Tyne, GB. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of six patents to his name, Miller's work focuses on developing compounds that have the potential to inhibit cancer cell growth.

Latest Patents

Miller's latest patents include the invention of isoindolinone inhibitors of the MDM2-P53 interaction, which exhibit anticancer activity. The invention provides a compound of a specific formula, along with its tautomers, solvates, and pharmaceutically acceptable salts. Additionally, the patents detail pharmaceutical compositions containing these compounds, processes for their synthesis, and their medical applications.

Career Highlights

Throughout his career, Duncan Charles Miller has worked with prominent organizations in the pharmaceutical sector. Notably, he has been associated with Astex Therapeutics Limited and Cancer Research Technology Limited. His work in these companies has allowed him to advance his research and contribute to the development of new cancer therapies.

Collaborations

Miller has collaborated with esteemed colleagues in his field, including Bernard Thomas Golding and Ian Robert Hardcastle. These partnerships have further enriched his research and innovation efforts.

Conclusion

Duncan Charles Miller stands out as a significant figure in the realm of cancer research, with his innovative patents paving the way for potential advancements in treatment. His contributions continue to inspire future research in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…